GLMD Projected Dividend Yield
Galmed Pharmaceuticals Ltd. ( NASDAQ : GLMD )Galmed Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of Aramchol, a liver targeted stearoyl-coenzyme A desaturase-1 modulator oral therapy for the treatment of non-alcoholic steato-hepatitis (NASH) for various populations. Co. is also collaborating with the Hebrew University in the development of Amilo-5MER, a 5 amino acid synthetic peptide. Co.'s product candidate, Aramchol, is a synthetic fatty acid-bile acid conjugate molecule that Co. is developing for oral treatment for NASH in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. 20 YEAR PERFORMANCE RESULTS |
GLMD Dividend History Detail GLMD Dividend News GLMD Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |